Dexmedetomidine
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
- Dexmedetomidine
- Dexmedetomidine: From Sedation to Nephrogenic Syndrome of Inappropriate Antidiuresis
Dexmedetomidine: From Sedation to Nephrogenic Syndrome of Inappropriate Antidiuresis
One-Sentence Summary
Dexmedetomidine is an alpha-2 adrenergic agonist marketed in Singapore as an injectable sedative. Its approved indication text is not available in the data compiled for this report. The TxGNN model's top-ranked prediction is nephrogenic syndrome of inappropriate antidiuresis (NSIAD), but there are 0 clinical trials and 0 publications supporting it, so it is a model prediction only. The best-supported alternative is headache disorder (specifically post-dural puncture headache), with 4 clinical trials and 7 publications. It is covered in the notes below.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available (the approved indication text is empty in all registrations) |
| Predicted New Indication | Nephrogenic syndrome of inappropriate antidiuresis |
| TxGNN Prediction Score | 99.60% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 8 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the compiled data. Based on general pharmacology, dexmedetomidine is an alpha-2 adrenergic agonist that reduces sympathetic outflow and may influence vasopressin release.
NSIAD is caused by gain-of-function mutations in the vasopressin V2 receptor (AVPR2). These act downstream of vasopressin secretion, so a reduction in vasopressin release would not be expected to correct the disease. The mechanistic link is therefore weak, and the high score is likely a graph-based association rather than a pharmacological rationale. No trials or literature were found.
Better-supported candidates from the same analysis:
- Headache disorder (score 99.30%, L2): Nebulized dexmedetomidine has been studied for post-dural puncture headache (PDPH). Proposed mechanisms include alpha-2 mediated modulation of pain and central sensitization, and possible effects on cerebral blood flow. The evidence is specific to PDPH, a secondary headache, and does not extend to primary headache disorders.
- Migraine disorder (score 99.49%, L5): One recruiting trial exists (NCT07769255). It has no results yet.
- Pulmonary hypertension (score 98.40%, L3): Evidence mainly supports safe sedation in patients with pulmonary hypertension, not disease-modifying treatment.
- Migraine with brainstem aura, trigeminal autonomic cephalalgia, hypotrichosis simplex of the scalp, atrophoderma vermiculata and congenital hypotrichosis milia: prediction only, with no trials or literature. The hair and skin conditions have no plausible mechanistic link and are likely graph artifacts.
- Migraine with or without aura, susceptibility to (L4): Only preclinical or tangential literature, such as work on cortical spreading depression.
Clinical Trial Evidence
Currently no related clinical trials registered for NSIAD.
For reference, the trials below are for the best-supported alternative, headache disorder:
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT04910477 | Phase 3 | Completed | 90 | Nebulized dexmedetomidine vs neostigmine/atropine for PDPH after cesarean section; single-center, active comparator, no placebo arm |
| NCT04327726 | N/A | Completed | 43 | Randomized study of nebulized dexmedetomidine for PDPH in parturients |
| NCT06470854 | N/A | Completed | 50 | Nebulized dexmedetomidine vs bilateral greater occipital nerve block for PDPH; non-randomized case-control |
| NCT03513757 | Phase 4 | Completed | 40 | Propofol infusion vs dexmedetomidine plus propofol for pediatric MRI sedation; headache link is incidental |
Literature Evidence
Currently no related literature available for NSIAD.
For reference, the main publications for headache disorder:
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 41120897 | 2025 | Systematic review | BMC Anesthesiology | Meta-analysis of nebulized dexmedetomidine for PDPH after cesarean delivery |
| 36651373 | 2023 | RCT | Minerva Anestesiologica | Nebulized dexmedetomidine vs neostigmine/atropine for PDPH after cesarean section |
| 33993346 | 2021 | RCT | Journal of Anesthesia | Adding nebulized dexmedetomidine to conservative PDPH management; cerebral hemodynamics assessed by transcranial Doppler |
| 39799300 | 2025 | Case report | BMC Anesthesiology | Two cases of obstetric PDPH treated with nebulized dexmedetomidine |
| 31345663 | 2019 | Editorial | Int J Obstet Anesth | Commentary on dexmedetomidine nebulization for PDPH |
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN11333P | Precedex Concentrate for Solution for Infusion 100 mcg/ml (Vial) | Injection | Not available |
| SIN16767P | Dexdor Concentrate for Solution for Infusion 100 micrograms/ml | Infusion, solution concentrate | Not available |
| SIN16592P | Icunes Concentrate for Solution for Infusion 100mcg/ml | Infusion, solution concentrate | Not available |
| SIN16554P | Dexmedetomidine Kalceks Concentrate for Solution for Infusion 100mcg/ml | Infusion, solution concentrate | Not available |
| SIN16908P | Dexmedetomidine Fresenius Concentrate for Solution for Infusion 100mcg/ml | Injection | Not available |
Eight valid single-ingredient registrations exist in total. All are injectable.
Safety Considerations
- Contraindication-related conditions (knowledge graph, not label text): hypertensive disorder, hypertension, kidney disease, pyoureter, liver disease, gallbladder disease, diabetes mellitus, diabetic ketoacidosis, hypotensive disorder, atrioventricular block.
- Drug Interactions: 59 interactions were recorded. Moderate-level interactions include morphine (including liposomal), opium, dronabinol, nabilone, diphenoxylate, ethanol, papaverine, sibutramine, amyl nitrite, diazoxide and phentolamine. These are mostly additive sedative or blood-pressure-lowering effects. Several others, such as pantoprazole, lansoprazole, vancomycin, atropine and famotidine, have an unknown severity level.
- Published safety signals (from the pulmonary hypertension literature): bradycardia and rare reports of asystole in children during infusion, and systemic and pulmonary vasoconstriction after loading doses.
Please refer to the package insert for label warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The top-ranked prediction (NSIAD) rests on the model score alone. It has no trials or literature, and its mechanistic link is weak, because the disease originates at the V2 receptor, downstream of vasopressin release. The label warnings are also unavailable, which blocks safety screening. Among the other predictions, headache disorder (PDPH) is the most promising and could be pursued as a separate research question.
To proceed, the following is needed:
- HSA package insert warnings, contraindications and approved indications
- Mechanism of action data (for example from DrugBank)
- For NSIAD: a mechanistic justification and any preclinical data, or deprioritization in favor of better-supported indications
- For PDPH: larger multicenter RCTs, ideally placebo-controlled, plus evidence for the Singapore-registered injectable forms (the studies used nebulized administration, and route compatibility has not been assessed)
- A safety plan for hemodynamic effects (bradycardia, hypotension), given the knowledge-graph contraindication signals
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.